MICROBIOME SEQUENCING SERVICE MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Market Size and Trends

Global microbiome sequencing service market is estimated to be valued at USD 1.97 Bn in 2024 and is expected to reach USD 4.13 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 11.1% from 2024 to 2031.

To learn more about this report, request a free sample copy

Global microbiome sequencing service market is expected to witness significant growth during the forecast period. This can be attributed to factors such as increasing R&D investment and field trials for gut microbiome-based drug development. Additionally, continual technological advancements in sequencing platforms and bioinformatics solutions are supporting high-throughput studies. Rising focus on human microbiome transplants and personalized probiotics as alternative treatment options for various conditions are another key trend driving investments in microbiome profiling services. Expanding applications of microbiome studies in healthcare, industrial, and environmental sectors will further promote market growth over the next few years.

Increasing Service Launches by Key Market Players

Increasing adoption of organic growth strategies such as service launch is expected to drive the market growth over the forecast period. For instance, on February 21, 2024, ALS Limited, a provider of comprehensive testing solutions, announced that it had launched the Gut Microbiome Sequencing service, offering researchers around the world a complete solution for obtaining comprehensive, publication-ready data to deliver in-depth insights into the human and animal gut microbiome. The microbiome sequencing service includes the use of cutting-edge technologies: Invitek Diagnostics Sample Collection Tubes, which allow shelf-stable storage of stool samples for up to 3 months

Market Concentration and Competitive Landscape

To learn more about this report, request a free sample copy

The key market players are focused on partnerships among key market players which in turn is expected to drive the market growth. For instance, in June 2022, CosmosID, a leading microbial genomics company, and Locus Biosciences Inc., a clinical-stage biotechnology company, announced a partnership for long-term support for clinical trial initiatives. CosmosID’s support for microbiome analysis is expected to assist Locus Biosciences Inc., in strengthening its precision therapeutics platform.

To learn more about this report, request a free sample copy

The requirement for specialized infrastructure and bioinformatics tools poses a significant challenge for the growth of microbiome sequencing service market. Processing and analyzing the vast amounts of data generated through microbiome sequencing requires high computational power and storage. It involves complex techniques like pre-processing of raw sequence reads, alignment to reference databases, taxonomy assignment, phylogenetic and functional analysis. Performing these steps demand clustering computing systems, high-bandwidth networks, huge storage arrays and advanced analytics software capable of handling petabytes of genomic and metabolic information. Setting up such a robust bioinformatics pipeline requires tremendous investment of capital and resources. This acts as a major deterrent for smaller labs and research institutions to offer microbiome sequencing as a service.

Market Opportunity – Targeted Drug Discovery based on Human and Environmental Microbiome Insights

Targeted drug discovery based on human and environmental microbiome insights can provide great opportunities in the microbiome sequencing service market. The human microbiome, which consists of trillions of microbes playing an important role in health, is an untapped source for the discovery of novel drugs, disease biomarkers and probiotics. Sequencing the microbiome communities inhabiting body, coupled with meta-omics analysis, can help gain in-depth insights about the microbes and their role in various diseases. This knowledge can further aid in developing precision diagnostics and therapeutics. For example, microbiome-based research has linked altered gut bacteria with various diseases like diabetes, obesity, cancer etc. and led to identification of potential drug targets and probiotics.

To learn more about this report, request a free sample copy

Service Type segment is sub-segmented into 6S rRNA gene profiling, whole genome shotgun sequencing, targeted gene sequencing, single-cell sequencing, others. The 6S rRNA gene profiling sub-segment is estimated to hold 35.3% of the market share in 2024 owing to its unmatched potential for comprehensive microbial profiling. As the foundational unit of bacterial identification, the 6S rRNA gene allows for cataloging of entire microbial communities through sequencing. Compared to targeted assays focusing on only several hundred species, 16S profiling embraces microbial diversity through an unbiased survey of both cultivated and uncultivated bacteria. This has become invaluable for exploring microbiomes in various host and environmental settings. Being a genomic fingerprint, 16S profiling can discern microbes even when whole genomes are unavailable. As sequencing costs drop, it has grown as a first-line investigation into microbiota composition before subsequent assays. Its standardization as a marker gene also makes results readily comparable across studies. Reference databases continue expanding recognition of microbial taxa detectable by 16S. Moreover, lower material requirements have boosted applications to difficult-to-access microbiome sites. Consistently delivering phylogenetic clues down to the genus/species level, 16S remains the workhorse enabling microbiome-guided discoveries.

Insights, By Application: Gastrointestinal Flora Holds Key to Future Therapies

Application segment is sub-segmented into gut microbiome analysis, urinary microbiome analysis, and others. The gut microbiome analysis sub-segment is estimated to hold 40.3% of the market share in 2024 owing to its immense significance to human health and disease. As the densest microbial community interfacing with the host, the gut microbiota perform essential roles in nutrition, metabolism, immunity and neurobiology. Dysbiosis of this intricate ecosystem has been linked to a wide range of gastrointestinal, metabolic and extra-intestinal disorders. Sequencing gut microbes illuminates their structure-function relationships and influence on pathology. Detection of novel butyrate-producing species or pathogens helps formulate dietary/pharmacological interventions. Tracking compositional shifts during therapies assesses clinical responses. Personalized diagnostics and therapeutics increasingly rely on characterization of patient-specific enterotypes. Probiotic formulation and prebiotic design also benefit from targeting keystone taxa identified by community profiling. With ever stronger associations emerging, gut microbiome analysis remains at the forefront of precision medicine approaches.

Insights, By End User: Discovery Drive Propels Academic Participation

End User segment is sub-segmented into academic and research institutes, pharmaceutical and biotechnology companies, diagnostic laboratories others. The academic and research institutes sub-segment is estimated to hold 38.2% of the market share in 2024, due to their pioneering discovery efforts. Universities and research organizations spearhead basic investigations to elucidate microbial function, host interactions and ecological principles governing assemblages. Their curiosity-driven inquiries lay foundations for applied microbiome fields. Being early adopters of emerging sequencing technologies, academics continually optimize protocols and expand reference databases. Large cohort studies involving healthy and diseased populations help establish benchmark representations. Multi-omic analyses integrating metagenomics with metabolomics, transcriptomics and more also become platforms within their laboratories. International initiatives are coordinating data sharing to accelerate insights. By training future scientists and spawning start-ups, academic research seeds the next generation of microbiome innovators.

Regional Insights

To learn more about this report, request a free sample copy

North America remains the dominant region in the global microbiome sequencing service market and is estimated to hold 37.4% of the market share in 2024 due to the presence of prominent market players and strong healthcare research infrastructure. Most of the leading service providers such as Illumina, Qiagen, and CosmosID are headquartered in the U.S. and have extensive operations across the region to cater to the high demand. In addition, North America hosts R&D centers of several pharmaceutical and biotechnology companies that employ microbiome sequencing services for drug discovery and development activities. The region also has a favorable reimbursement environment and growing awareness about clinical applications of microbiome research which drives the market growth. Furthermore, the thriving academics ecosystem in the U.S. and Canada contributes significantly through funded research projects involving microbiome sequencing.

Asia Pacific has emerged as the fastest growing regional market for microbiome sequencing services. Countries such as China, Japan, South Korea, and India offer immense opportunities for market expansion owing to rise in healthcare investments, increasing focus on preventive medicines, and growing collaboration between regional and global players. Local players in Asia are investing heavily to establish themselves through partnerships, acquisitions and by expanding their portfolio. This has encouraged technology transfer and enhanced accessibility of advanced sequencing technologies. Moreover, the low labor and operating costs make the region an attractive outsourcing destination for large sequencing projects. Rising disposable income has also increased affordability of such specialized services. Several global service providers now have established regional hubs and local partner laboratories across major Asian countries to capitalize on this fast-paced growth.

Market Report Scope

Key Developments

• On April 23, 2024, Clinical Microbiomics A/S, a leader in microbiome analysis, announced that it had launched advanced Long-Read 16S, ITS, 18S, isolate, and metagenomics sequencing services to meet the stringent requirements of academic, clinical, and industrial researchers, the expanded offerings deliver unmatched insights into microbial communities. The service features include longer reads, high-quality scores, comprehensive workflow, advanced bioinformatics, user-friendly software, etc.
• In November 2023, QIAGEN, a global biotechnology company, announced the launch of the Microbiome WGS (whole-genome sequencing) SeqSets, a comprehensive Sample to Insight workflow designed to provide an easy-to-use solution that maximizes efficiency and reproducibility in microbiome research
• In May 2023, Zymo Research Corporation, a key player in epigenetics, microbiomics, and Next-Gen Sequencing, announced the launch of its Full-Length 16S Sequencing Service, offering researchers high-quality, full-length 16S rRNA gene sequencing for microbiome analysis. The new full-length 16S service provides researchers with greater species resolution and increased data quality while maintaining a cost-effective approach when compared to historic, short-read 16S sequencing.
• In March 2022, Diversigen, a microbiome and metagenomics services provider, announced the launch of a new human gut microbiome testing service for comprehensive gastrointestinal testing solutions. The solutions are accessible to healthcare professionals through brand name CO-Biome.

*Definition: The microbiome sequencing services provide sequencing and analysis of the microorganisms that inhabit the human body, including bacteria, fungi and viruses. These services sequence the DNA or RNA of the microbiome using next-generation sequencing technology to characterize the microbial composition of clinical or environmental samples. They analyze the sequencing data to determine the taxonomy and functional potential of microbes present. Microbiome sequencing service providers help researchers and medical professionals better understand the relationship between the microbiome and human health or environmental conditions.

Market Segmentation

•  Service Type Insights (Revenue, USD Bn, 2019 - 2031)
  • 6S rRNA gene profiling
  • Whole genome shotgun sequencing
  • Targeted gene sequencing
  • Single-cell sequencing
  • Others
•  Application Insights (Revenue, USD Bn, 2019 - 2031)
  • Gut microbiome analysis
  • Urinary microbiome analysis
  • Others
•  End User Insights (Revenue, USD Bn, 2019 - 2031)
  • Academic and research institutes
  • Pharmaceutical and Biotechnology companies
  • Diagnostic laboratories
  • Others
• Regional Insights (Revenue, USD Bn, 2019 - 2031)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Microbiome Insights Inc.
  • Baseclear B.V. 
  • Clinical Microbiomics A/S
  • Mérieux NutriSciences Corporation
  • MR DNA
  • Zymo Research Corporation
  • Metabiomics Corp.
  • uBiome, Inc.
  • Microbiome Therapeutics Innovation Group
  • Locus Biosciences, Inc.
  • OpenBiome
  • Shanghai Ruiyi Biotechnology Co., Ltd.
  • Resphera Biosciences, LLC
  • Molzym GmbH & Co. KG
  • BioSpherex LLC